Fmr LLC Buys 327,498 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Fmr LLC increased its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 12,963,151 shares of the company’s stock after purchasing an additional 327,498 shares during the period. Fmr LLC owned 0.15% of IDEAYA Biosciences worth $333,153,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in IDYA. State Street Corp lifted its holdings in shares of IDEAYA Biosciences by 15.4% in the third quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after buying an additional 443,640 shares in the last quarter. Barclays PLC increased its holdings in IDEAYA Biosciences by 188.8% during the 3rd quarter. Barclays PLC now owns 181,170 shares of the company’s stock worth $5,739,000 after acquiring an additional 118,438 shares during the period. Verition Fund Management LLC purchased a new stake in IDEAYA Biosciences in the 3rd quarter worth approximately $246,000. Geode Capital Management LLC boosted its holdings in IDEAYA Biosciences by 9.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company’s stock valued at $61,645,000 after purchasing an additional 172,838 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of IDEAYA Biosciences by 444.2% during the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company’s stock valued at $475,000 after purchasing an additional 15,089 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $15.77 on Friday. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -4.78 and a beta of 0.51. The business has a 50 day moving average of $19.01 and a 200 day moving average of $24.39. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $7.00 million. As a group, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Upgrades and Downgrades

IDYA has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Stephens restated an “overweight” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Wedbush restated an “outperform” rating and issued a $52.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.